NasdaqGM:RYTMBiotechs
Could A New Bardet-Biedl Diagnostic Algorithm Subtly Reshape Rhythm Pharmaceuticals’ (RYTM) Rare-Disease Reach?
Rhythm Pharmaceuticals recently announced the publication of a new, consensus-driven diagnostic algorithm for Bardet-Biedl syndrome in the American Journal of Medical Genetics, alongside multiple upcoming clinical data presentations on setmelanotide and bivamelagon at ENDO 2026.
The new algorithm, created with international experts and patient groups, aims to speed and broaden clinical diagnosis of Bardet-Biedl syndrome by integrating updated clinical criteria and advances in genetic...